Error loading player: No playable sources found

We Share Our Planet - Options to Remove Animals and/or Animal- derived Reagents from Release Testing

Date
January 27, 2022
This product is not available for individual purchase, but it is available as part of the following products:

Use of animals and/or animal derived products to demonstrate safety or efficacy supports drug development and, in some cases, is required by law to release drug product. Much progress has been made since the early days of drug testing to remove or minimize the use of animals in facilitating release testing of drug products. New technologies are helping us limit animal usage while providing more precise and accurate results. This session will take a look at some of those tests such as potency and endotoxin and review ongoing activities working to reduce or eliminate the use of animals in release testing. The goal of this session is to inspire change by providing actionable information and review ongoing efforts to reduce our reliance on those who share our planet.

Session Speakers:
08:30 - 08:55
Recombinant Factor C: An Approved and Sustainable Bacterial Endotoxins Test
IP Jay Bolden, Eli Lilly and Company

08:55 - 09:20
Transition of an Animal-based Bioassay: Somatropin Case Study
V Kevin Carrick, US Pharmacopeia (USP)



09:20 - 09:45
Removing Animals and Reagents Derived from Animals for Testing
V Robin Levis, CBER, FDA

09:45 - 10:00
Discussion – Questions and Answers

Speakers

Speaker Image for Jay Bolden
Eli Lilly and Company
Speaker Image for Kevin Carrick
US Pharmacopeia (USP)

Related Products

Thumbnail for “Alone We Can Do So Little, Together We Can Do So Much” - How Did 25 Years of WCBP Conferences Shape Our Thinking and Our Way of Working?
“Alone We Can Do So Little, Together We Can Do So Much” - How Did 25 Years of WCBP Conferences Shape Our Thinking and Our Way of Working?
“Alone we can do so little, together we can do so much” is a Helen Keller quote which captures the spirit of CASSS-organized conferences like WCBP, the regional CMC strategy forums, and technology specific meetings…
Thumbnail for Accelerating Vaccine Development Through Technology Platforms
Accelerating Vaccine Development Through Technology Platforms
Industry and regulatory authorities speed of response to the COVID-19 pandemic crisis demonstrated the capability to develop new therapeutics in the face of a dire situation…
Thumbnail for Next Steps from Speed to Patients
Next Steps from Speed to Patients
In today’s world being able to supply medicines to patients faster is not only a competitive advantage but of critical importance for saving lives…